Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12184558 | 1.00 | STS (0.43) | STSNR1H2NR1H3JAK2JAK1 | |
| SCHEMBL13086596 | 0.82 | KLK7 (0.49) | NR1H2NR1H3 | |
| SCHEMBL3046705 | 0.82 | KLK7 (0.49) | NR1H2NR1H3 | |
| SCHEMBL2689602 | 0.82 | KLK7 (0.49) | NR1H2NR1H3 | |
| SCHEMBL2597820 | 0.80 | KLK7 (0.41) | STSNR1H2NR1H3JAK2JAK1 | |
| SCHEMBL271604 | 0.77 | NR1H2 (0.59) | STSNR1H2NR1H3JAK2JAK1 | |
| SCHEMBL273407 | 0.77 | NR1H2 (0.59) | STSNR1H2NR1H3JAK2JAK1 | |
| SCHEMBL5637318 | 0.77 | NR1H2 (0.59) | STSNR1H2NR1H3JAK2JAK1 | |
| SCHEMBL2597799 | 0.77 | RIPK1 (0.49) | NR1H2NR1H3 | |
| SCHEMBL2597852 | 0.76 | KLK7 (0.41) | NR1H2NR1H3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | STS 608/4885NR1H2 2668/4885NR1H3 2970/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | STS 4579/4885NR1H2 1981/4885NR1H3 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.